

January 28, 2021
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Collaborative research with the Institute of Medical Science, the University of Tokyo,
to explore new indications for bendamustine and rigosertib**

TOKYO, Japan, January 28, 2021 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") announced today that it has entered into a joint research agreement with the Institute of Medical Science, the University of Tokyo ("IMSUT"), to explore potential new indications for bendamustine and rigosertib.

The collaboration will be between Symbio and Professor Toshio Kitamura, M.D., Ph.D., IMSUT Advanced Clinical Research Center, Division of Cellular Therapy. The research will use bendamustine and rigosertib in combination or with other approved drugs to explore efficacy and new indications. The pharmacological effects of bendamustine and rigosertib in combination and with other approved drugs will be explored by analyzing the epigenetic control of various tumor cells.

Professor Kitamura is an accomplished researcher and has a large network of physicians in the areas of hematopoietic stem cell differentiation and hematopoietic tumors such as leukemia. Professor Kitamura is also studying the molecular mechanisms in the development of hematopoietic tumors caused by epigenetic abnormalities, to develop novel therapies using hematopoietic tumor models.

Symbio will leverage its experience in development of anti-cancer drugs and collaborate with IMSUT to search for new indications for bendamustine and rigosertib that will fulfill both unmet medical needs and the company's business objectives.

Statement of Fuminori Yoshida, President and Chief Executive Officer of Symbio: "Going forward, Symbio will be actively involved in goal-oriented collaboration with academia to maximize business value by using bendamustine and rigosertib in combination or with other approved drugs to explore their potential."

Symbio does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2020. Performance forecasts for the fiscal year ending December 31, 2021 will be disclosed in the announcement of financial results summary for the fiscal year ending December 2020.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About TREAKISYM®

TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug first used in Germany in the 1970s, is now widely used in more than 50 countries with indications for low-grade non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

- TREAKISYM® Intravenous Infusion 100 mg was approved in October 2010 for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan.
- TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japan in August 2016.
- TREAKISYM® was approved for the additional indications of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December 2016.
- Symbio achieved the primary endpoint (overall response rate) in Phase III study of TREAKISYM® in combination with rituximab as treatment for r/r DLBCL and submitted a partial change application with respect to its marketing approval in May 2020.
- TREAKISYM® ready-to-dilute ("RTD") liquid formulation was approved in Japan in September 2020 and launches in January 2021.
- Symbio aims to achieve annual sales of JPY 10 billion on a NHI drug price basis at the earliest possible stage.

About Rigosertib

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. Symbio obtained the development and commercialization licensing rights for Rigosertib from Onconova in July 2011 for Japan and Korea.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer. Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. Clinical trials with Onconova's compound rigosertib are aimed at what Onconova believes are unmet medical needs of patients with cancer. For more information, please visit <https://www.onconova.com>.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.